scholarly journals Altered plasma, urine, and tissue profiles of sulfatides and sphingomyelins in patients with renal cell carcinoma

2022 ◽  
Author(s):  
Robert Jirásko ◽  
Jakub Idkowiak ◽  
Denise Wolrab ◽  
Aleš Kvasnička ◽  
David Friedecký ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Body Fluids ◽  
Tissue Samples ◽  
Cancer Occurrence ◽  
Urological Malignancies ◽  
Incidence And Mortality ◽  
Concentration Changes ◽  
Fatty Acyls

Renal cell carcinoma (RCC) represents the most common type of kidney cancer with the highest incidence and mortality rate among all urological malignancies. In this study, we show that RCC-related processes change body fluids sphingolipid concentrations, which may be used to monitor cancer occurrence in low-invasive lipid-based blood and urine tests. We investigate 674 plasma, urine, and tissue samples from 369 RCC patients and controls. For the first time, we show the significant concentration changes of low abundant sulfatides in plasma and urine of RCC patients. Elevated concentrations of lactosylsulfatides, decreased concentrations of sphingomyelines with long saturated N-fatty acyls and sulfatides with hydroxylated fatty acyls are the most crucial alternations in RCC. These changes are stage-dependent and are more emphasized in late-stage RCC. Similar trends in body fluids and tissues indicate that RCC widely influences lipid metabolism and highlights the potential of lipidomic profiling for cancer detection.

scholarly journals Synchronous ipsilateral renal cell carcinoma and urothelial carcinoma of the renal pelvis

2013 ◽  
Vol 3 (1) ◽  
pp. 64 ◽  
Author(s):  
Mike Leveridge ◽  
Phillip A. Isotalo ◽  
Alexander H. Boag ◽  
Jun Kawakami
Keyword(s):  
Renal Cell Carcinoma ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Renal Pelvis ◽  
Renal Cell ◽  
Preoperative Imaging ◽  
Time Of Surgery ◽  
Urological Malignancies ◽  
Carcinome Urothélial ◽  
Fresh Specimen

Renal cell carcinoma (RCC) and urothelial carcinoma of the upperurinary tract are not uncommon urological malignancies. Theirsimultaneous occurrence in a patient is, however, extraordinarilyrare. We report the case of a patient who underwent laparoscopicnephrectomy for suspected RCC. Preoperative imaging wassuspicious for renal pelvic involvement, which was confirmedupon bivalving the fresh specimen at the time of surgery, with thediscovery of a separate urothelium-based lesion. We discuss thisrare occurrence and our management approach.Individuellement, l’hypernéphrome et le carcinome urothélial desvoies urinaires supérieures ne sont pas des tumeurs urologiquesrares. Leur survenue simultanée chez un même patient est cependantextrêmement rare. La reconnaissance préopératoire ou intraopératoireest cruciale afin que soit effectuée la résection urétéralerequise. Nous décrivons un cas d’hypernéphrome et de carcinomeurothélial simultanés et homolatéraux.

Protein profiling of microdomains purified from renal cell carcinoma and normal kidney tissue samples

2012 ◽  
Vol 8 (4) ◽  
pp. 1007-1016 ◽  
Author(s):  
F. Raimondo ◽  
L. Morosi ◽  
C. Chinello ◽  
R. Perego ◽  
C. Bianchi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Kidney Tissue ◽  
Protein Profiling ◽  
Normal Kidney ◽  
Tissue Samples ◽  
Normal Kidney Tissue

scholarly journals A 17-Gene Signature Predicted Prognosis in Renal Cell Carcinoma

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Fan Li ◽  
Weifeng Hu ◽  
Wei Zhang ◽  
Guohao Li ◽  
Yonglian Guo
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Malignant Tumors ◽  
Prognostic Significance ◽  
Gene Signature ◽  
The Cancer Genome Atlas ◽  
Prognostic Indicators ◽  
Incidence And Mortality ◽  
Tcga Dataset

Renal cell carcinoma (RCC), which was one of the most common malignant tumors in urinary system, had gradually increased incidence and mortality in recent years. Although significant advances had been made in molecular and biology research on the pathogenesis of RCC, effective treatments and prognostic indicators were still lacking. In order to predict the prognosis of RCC better, we identified 17 genes that were associated with the overall survival (OS) of RCC patients from The Cancer Genome Atlas (TCGA) dataset and a 17-gene signature was developed. Through SurvExpress, we analyzed the expression differences of the 17 genes and their correlation with the survival of RCC patients in five datasets (ZHAO, TCGA, KIPAN, KIRC, and KIRP), and then evaluated the survival prognostic significance of the 17-gene signature for RCC. Our results showed that the 17-gene signature had a predictive prognostic value not only in single pathologic RCC, but also in multiple pathologic types of RCC. In conclusion, the 17-gene signature model was related to the survival of RCC patients and could help predict the prognosis with significant clinical implications.

scholarly journals LRG1 May Accelerate the Progression of ccRCC via the TGF-β Pathway

2020 ◽  
Vol 2020 ◽  
pp. 1-9 ◽  
Author(s):  
Quan Hong ◽  
Shuqiang Wang ◽  
Shuxin Liu ◽  
Xiangmei Chen ◽  
Guangyan Cai
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Kidney Tissue ◽  
The Cancer Genome Atlas ◽  
Gene Methylation ◽  
Cell Renal Cell Carcinoma ◽  
Tissue Samples ◽  
Downstream Signaling ◽  
Cancer Genome Atlas

Clear cell renal cell carcinoma (ccRCC) accounts for 60-70% of renal cell carcinoma (RCC) cases. It is an urgent mission to find more therapeutic targets for advanced ccRCC. Leucine-rich a-2-glycoprotein 1 (LRG1) is a secreted protein associated with a variety of malignancies. Our study focused on the expression and mechanism of LRG1 in ccRCC based on data from The Cancer Genome Atlas (TCGA) and provided primary verification including LRG1 expression detection, LRG1 gene methylation detection, and downstream signaling detection. We found that LRG1 was overexpressed in ccRCC kidney tissue samples, and the methylation level of LRG1 gene was significantly decreased in ccRCC. Moreover, the expression of LRG1 was negatively related to patient survival. Based on our previous study and the verification reported in this article, we propose that demethylation-induced overexpression of LRG1 is likely to accelerate ccRCC progression via the TGF-β pathway.

scholarly journals Increased expression of SET domain-containing proteins and decreased expression of Rad51 in different classes of renal cell carcinoma

2016 ◽  
Vol 36 (3) ◽  
Author(s):  
Si Liu ◽  
Yiyang Li ◽  
Hongmei Xu ◽  
Kaichen Wang ◽  
Nan Li ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Chromatin Immunoprecipitation ◽  
Renal Cell ◽  
Specific Binding ◽  
Set Domain ◽  
Tissue Samples

Because of scant availability of tissue samples, we did not perform elaborate examination of chromatin immunoprecipitation and specific binding of SET domain-containing proteins to the promoters of Rad51. These remain avenues for future investigations.

scholarly journals Renal Cell Carcinoma – How Can We Predict its Outcomes in Clinical Practice?

2013 ◽  
Vol 13 (1) ◽  
pp. 63-70
Author(s):  
Ieva Vaivode ◽  
Vilnis Lietuvietis ◽  
Alinta Hegmane ◽  
Iveta Kudaba
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Predictive Accuracy ◽  
Treatment Strategies ◽  
Simple Algorithm ◽  
Mortality Data ◽  
Routine Practice ◽  
Clinical Scenarios ◽  
Incidence And Mortality

Summary Morbidity and mortality data of RCC (renal cell carcinoma) differs a lot among the European countries. In Latvia a growing trend in both incidence and mortality rates is still observed. The expanding availability of multiple treatment strategies has increased the importance of skilled individualized outcome prediction for patients. Several prognostic factors are available in RCC including anatomical, histological, clinical and molecular ones, but none of them is very precise, when used alone. Therefore increasing number of prognostic systems has been created in local and metastatic disease to increase predictive accuracy. In order to encourage the clinicians to use the available models in their routine practice, we tried to select the most relevant ones and include them in a simple algorithm to be used in common clinical scenarios throughout entire history of the disease in patients with RCC

scholarly journals Circulating biomarkers in renal cell carcinoma: the link between microRNAs and extracellular vesicles, where are we now?

2014 ◽  
Vol 1 (8) ◽  
pp. 84-98 ◽  
Author(s):  
Ana L Teixeira ◽  
Francisca Dias ◽  
Mónica Gomes ◽  
Mara Fernandes ◽  
Rui Medeiros
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Genetic Material ◽  
Tumor Development ◽  
Cell Communication ◽  
Bioactive Molecules ◽  
Screening Tests ◽  
Transcriptional Level ◽  
Incidence And Mortality

Renal cell carcinoma (RCC) is a lethal urological cancer, with incidence and mortality rates increasing by 2-3% per decade. The lack of   standard screening tests contributes to the fact that one-third of patients are diagnosed with locally invasive or metastatic disease. Moreover, 20-40% of RCC patients submitted to surgical nephrectomy will develop metastasis. MicroRNAs (miRNAs) are small non-coding RNAs responsible for gene regulation at a post-transcriptional level.  It is accepted that they are deregulated in cancer and can influence tumor development. Thus, miRNAs are promising RCC biomarkers, since they can be detected using non-invasive methods. They are highly stable and easier to quantify in circulating biofluids. The elevated miRNA stability in circulating samples may be the consequence of their capacity to circulate inside of extracellular microvesicles (EMVs), for example, the exosomes.  The EMVs are bilayered membrane vesicles secreted by all cell types. They can be released in the interstitial space or into circulating biofluids, which allows the travelling, binding and entrance of these vesicles in receptor cells. This type of cell communication can shuttle bioactive molecules between cells, allowing the horizontal transference of genetic material. In this review, we focus on circulating miRNAs (miR-210, miR-1233, miR-221, miR-15a, miR-451, miR-508, miR-378) in the biofluids of RCC patients and attempt to establish the diagnostic and prognostic accuracy, their synergic effects, and the pathways involved in RCC biology.

scholarly journals CENPF Promotes Proliferation of Renal Cell Carcinoma In Vitro

2021 ◽  
Author(s):  
Ji Zhang ◽  
Shushu Yuan ◽  
Hua Zhu ◽  
Zhan Chen ◽  
Zhenmin Liu ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Progression ◽  
Renal Cell ◽  
Drug Targets ◽  
Tissue Samples ◽  
Clinical Biomarkers

Abstract Background: Metastasis and drug resistance are the main causes of renal cell carcinoma (RCC) mortality. Currently, there are still limited number of targeted therapies against advanced RCC. It is critical to develop new effective clinical biomarkers and drug targets in RCC. Several studies have shown that Centromere protein F (CENPF), a microtubule binding protein, promotes cancer progression in various types of cancer. The purpose of this study is to explore the role of CENPF in RCC.Materials and methods: Peripheral blood and corresponding tissue samples of 23 RCC patients and 23 normal physical examination patients who were treated in our hospital from 2018 to 2020 were collected, and the CENPF expression was detected by qRT-PCR, Western-blot and immunohistochemical methods. Down-regulate the expression of CENPF by siRNA transfection, and detect the proliferation of the corresponding RCC cells and the corresponding cell cycle.Results: According to TCGA data analysis, CENPF is highly expressed in RCC, and its expression level is significantly related to the overall survival and recurrence-free survival of RCC. In addition, high expression of CENPF was found in the tissues of RCC patients in our hospital. Knockdown of CENPF can significantly reduce the proliferation of RCC cells in in vitro experiments, and knockdown of CENPF can regulate the cell cycle by inhibiting the expression of cyclins such as CDK4, CDK6 and CyclinD1. Conclusion: CENPF can be used as an independent prognostic factor of RCC and regulate the proliferation ability and cell cycle of RCC cells. CENPF is a potential oncogene and prognostic marker in RCC.

scholarly journals Long noncoding RNA SNHG4 promotes renal cell carcinoma tumorigenesis and invasion by acting as ceRNA to sponge miR-204-5p and upregulate RUNX2

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Jie Wu ◽  
Tingting Liu ◽  
Lulu Sun ◽  
Shaojin Zhang ◽  
Gang Dong
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Proliferation ◽  
Tumor Growth ◽  
Cell Carcinoma ◽  
Mouse Models ◽  
Cell Lines ◽  
Renal Cell ◽  
Cell Counting ◽  
Tissue Samples ◽  
Qrt Pcr

Abstract Background Long noncoding RNAs (lncRNAs) are involved in the tumorigenesis and progression of human cancers, including renal cell carcinoma (RCC). Small nucleolar RNA host gene 4 (SNHG4) is reported to play an essential role in tumor growth and progression. However, the molecular mechanisms and function of SNHG4 in RCC remain undocumented. Methods Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to examine expression levels of SNHG4 in RCC tissue samples and cell lines. Cell counting kit-8, western blotting, activities of caspase-3, -8, and -9, wound-healing, and transwell invasion assays were performed to explore cell proliferation, apoptosis, migration, and invasion. The interaction among SNHG4, miR-204-5p, and RUNX2 was verified by bioinformatic analysis, a luciferase gene report, qRT-PCR, western blot analysis, and RNA immunoprecipitation assays. Xenograft mouse models were carried out to examine the role of SNHG4 in RCC in vivo. Results SNHG4 was highly expressed in RCC tissue samples and cell lines, and its upregulation was significantly involved in node involvement, distant metastasis, and reduced overall and relapse-free survival of patients with RCC. SNHG4 acted as an oncogenic lncRNA with promoted RCC cell proliferation, migration, invasion, and inhibited apoptosis. SNHG4 boosted tumor growth in xenograft mouse models. Mechanistically, SNHG4 functioned as a competing endogenous RNA (ceRNA) for sponging miR-204-5p, leading to the upregulation of its target RUNX2 to promote RCC cell proliferation and invasion. Conclusion SNHG4 and miR-204-5p might be indicated in RCC progression via RUNX2, suggesting the potential use of SNHG4/miR-204-5p/RUNX2 axis in RCC treatment.

Association of reduced GATA1 mRNA expression with clinicopathology and shortened recurrence-free survival in clear cell renal cell carcinoma.

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 521-521
Author(s):  
Inga Peters ◽  
Natalia Dubrowinskaja ◽  
Michael Kogosov ◽  
Mahmoud Abbas ◽  
Joerg Hennenlotter ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Tumor Progression ◽  
Cell Carcinoma ◽  
Mrna Expression ◽  
Distant Metastasis ◽  
Renal Cell ◽  
Clear Cell ◽  
Tissue Samples ◽  
P53 Expression ◽  
Expression Levels

521 Background: GATA1, a zinc-finger transcription factor and member of the GATA family proteins 1-6, is known to be involved in cell growth and apoptosis, especially in the erythroid lineage. Recent studies demonstrated that GATA1 interacts with p53 and its overexpression leads to an inhibition of the p53 gene function. Increased p53 expression levels have been shown to be associated with prognosis and tumor progression in renal cell carcinoma. Methods: Quantitative real-time reverse-transcribed polymerase chain reaction was applied to measure relative GATA1 mRNA expression levels in 135 kidney tissue samples, including 77 clear cell RCC (ccRCC) tissues and 58 paired adjacent normal renal tissue samples. Relative GATA1 expression levels were determined using the ΔΔCt method. Results: The mean GATA1 expression levels were significantly decreased in tumor tissues compared to adjacent normal tissues (p < 0.001, paired t-test). In univariate logistic regression analysis decreased GATA1 mRNA expression was associated with advanced tumor disease (p = 0.005), positive status of distant metastasis (p = 0.03) and lymph node metastasis (p = 0.011). Reduced GATA1 expression was associated with an increase risk of disease recurrence (p = 0.005, hazard ratio HR = 0.05). Status of distant metastasis remained also a significant independent parameter in the bivariate Cox regression model (p = 0.05, HR = 3.01). Conclusions: GATA1 mRNA expression is reduced in ccRCC and associates with a poor clinical outcome and worse clinicopathology, indicating a possible role of GATA1 in tumor development and aggressiveness of ccRCC. GATA1 could therefore serve as a new biomarker for tumor progression in ccRCC.

Sign in / Sign up

Export Citation Format

Share Document